Double blind study of furosemide for Acute Kidney Injury(AKI)

Double blind study of furosemide for Acute Kidney Injury(AKI) - Furosemide for AKI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046093

Enrollment

Registered

2021-12-01

Start date

2025-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Interventions

Normal saline 0.2ml/kg/h for placebo group will be administered for first 6 hours since AKI is recognized. When urine amount is gained over 3ml/kg/h, the drug is reduced by 0.05ml/kg/h with every 2 ho

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ICU patients and KDIGO AKI score more than one

Exclusion criteria

Exclusion criteria: Patients on hemodiafiltration

Design outcomes

Primary

Measure	Time frame
Renal function for 30 days since Acute Kidney Injury was recognized	—

Secondary

Measure	Time frame
Duration of ICU stay, Duration of hospital stay, usage of RRT	—

Countries

Japan

Contacts

Public ContactMasao Hayashi

Kawasaki medical school general medical center Anesthesiology and Intensive care medicine 3

mao893@aol.com086-225-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026